Taiwan Launches NT$10 Billion Fund to Boost Biotech Innovation and Global Expansion
Taiwan is taking a major step to strengthen its biomedical industry with the approval of a new NT$10 billion, or roughly US$308 million, investment program aimed at accelerating biotech commercialization and global market growth.
The National Development Fund Management Committee approved the 10-year initiative on August 4, signaling the government’s commitment to turning Taiwan’s biomedical research strengths into internationally competitive businesses. The program is designed to support companies developing innovative technologies with strong clinical value, clear commercial potential, and opportunities to expand beyond the domestic market.
The fund is expected to play an important role in helping Taiwan’s biotech firms move from research and development into real-world medical applications. By focusing on companies with promising clinical use cases, the initiative aims to encourage the development of new treatments, medical technologies, diagnostics, and healthcare solutions that can address growing global demand.
Taiwan has been working to position itself as a key player in the global biotechnology and healthcare sectors. With strong foundations in precision manufacturing, medical research, digital technology, and semiconductor-related innovation, the country is looking to create deeper connections between local biotech companies and international markets.
The NT$10 billion program is also expected to help reduce funding barriers for biomedical startups and growth-stage firms. Commercializing biotech products often requires long development timelines, regulatory approvals, clinical validation, and significant capital. Government-backed investment can provide critical support during these stages, making it easier for promising companies to scale their operations and attract additional private investment.
By targeting businesses with international market potential, Taiwan hopes to build a stronger pipeline of biotech firms capable of competing globally. The initiative may also encourage partnerships between local companies, research institutions, hospitals, and overseas industry players.
The new investment program reflects Taiwan’s broader strategy to make biotechnology one of its key growth industries over the next decade. As demand rises for advanced healthcare solutions worldwide, the government is aiming to help local innovators transform scientific breakthroughs into commercial products with global impact.
With NT$10 billion in long-term backing, Taiwan’s biomedical sector could gain fresh momentum, opening new opportunities for innovation, investment, and international collaboration.
